A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Mesothelioma|Mesotheliomas Pleural|Mesothelioma, Malignant|Mesothelioma Peritoneum|Ovarian Cancer|Ovarian Serous Adenocarcinoma|Pancreatic Cancer|Pancreatic Adenocarcinoma|Colorectal Cancer|Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer|Ovarian Adenocarcinoma|Pancreatic Neoplasms|Colorectal Neoplasms|Ovarian Neoplasms|Cholangiocarcinoma|Non Small Cell Lung Cancer
Interventions: BIOLOGICAL: TC-510|DRUG: Fludarabine|DRUG: Cyclophosphamide
Sponsor: TCR2 Therapeutics